AU2020275304B2 - Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions - Google Patents

Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Download PDF

Info

Publication number
AU2020275304B2
AU2020275304B2 AU2020275304A AU2020275304A AU2020275304B2 AU 2020275304 B2 AU2020275304 B2 AU 2020275304B2 AU 2020275304 A AU2020275304 A AU 2020275304A AU 2020275304 A AU2020275304 A AU 2020275304A AU 2020275304 B2 AU2020275304 B2 AU 2020275304B2
Authority
AU
Australia
Prior art keywords
nmr
mmol
mhz
ripk3
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020275304A
Other languages
English (en)
Other versions
AU2020275304A1 (en
Inventor
Siddharth Balachandran
Gregory Cuny
Alexei Degterev
Sameer NIKHAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Cancer Research
Tufts University
University of Houston System
Original Assignee
Institute For Cancer Res D/b/a Res Institute Of Fox Chase Cancer Center
Institute for Cancer Research
Tufts University
University of Houston System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Cancer Res D/b/a Res Institute Of Fox Chase Cancer Center, Institute for Cancer Research, Tufts University, University of Houston System filed Critical Institute For Cancer Res D/b/a Res Institute Of Fox Chase Cancer Center
Publication of AU2020275304A1 publication Critical patent/AU2020275304A1/en
Application granted granted Critical
Publication of AU2020275304B2 publication Critical patent/AU2020275304B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2020275304A 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions Active AU2020275304B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962848648P 2019-05-16 2019-05-16
US201962848719P 2019-05-16 2019-05-16
US62/848,648 2019-05-16
US62/848,719 2019-05-16
PCT/US2020/032784 WO2020232190A1 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Publications (2)

Publication Number Publication Date
AU2020275304A1 AU2020275304A1 (en) 2021-12-16
AU2020275304B2 true AU2020275304B2 (en) 2025-01-23

Family

ID=70919255

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020275304A Active AU2020275304B2 (en) 2019-05-16 2020-05-14 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Country Status (6)

Country Link
US (1) US12516055B2 (https=)
EP (2) EP4480485A3 (https=)
JP (2) JP7546603B2 (https=)
AU (1) AU2020275304B2 (https=)
CA (1) CA3137869A1 (https=)
WO (1) WO2020232190A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174255B2 (en) * 2017-05-15 2021-11-16 University Of Houston System Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
EP4480485A3 (en) * 2019-05-16 2025-02-26 University of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CN113072471B (zh) * 2021-03-02 2022-09-16 四川美大康华康药业有限公司 一种利非司特中间体及其制备方法
WO2024097805A1 (en) * 2022-11-01 2024-05-10 Trustees Of Tufts College Mixed lineage kinase domain like pseudokinase (mlkl) activators
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
KR20020070520A (ko) 2000-01-27 2002-09-09 워너-램버트 캄파니 신경퇴행성 질병의 치료를 위한 피리도피리미디논 유도체
WO2014031571A1 (en) * 2012-08-21 2014-02-27 Icahn School Of Medicine At Mount Sinai Treatment of viral infections
WO2015179436A1 (en) 2014-05-19 2015-11-26 Sanford-Burnham Medical Research Institute Inflammation therapy using mekk3 inhibitors or blocking peptides
EP4480485A3 (en) * 2019-05-16 2025-02-26 University of Houston System Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases

Also Published As

Publication number Publication date
EP4480485A3 (en) 2025-02-26
US20220194937A1 (en) 2022-06-23
US12516055B2 (en) 2026-01-06
AU2020275304A1 (en) 2021-12-16
JP2022533182A (ja) 2022-07-21
WO2020232190A1 (en) 2020-11-19
JP7546603B2 (ja) 2024-09-06
EP3968991B1 (en) 2024-07-31
CA3137869A1 (en) 2020-11-19
EP3968991A1 (en) 2022-03-23
EP3968991C0 (en) 2024-07-31
JP2024170457A (ja) 2024-12-10
EP4480485A2 (en) 2024-12-25

Similar Documents

Publication Publication Date Title
AU2020275304B2 (en) Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions
CN114555588B (zh) 作为axl抑制剂的喹唑啉类化合物
CA3203205A1 (en) Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer
TWI393566B (zh) 作為週期素依賴性激酶之新穎吡唑并嘧啶
AU2017268536B2 (en) Novel compounds and compositions for inhibition of FASN
US10087195B2 (en) Certain protein kinase inhibitors
AU2025237955A1 (en) KRAS G12C inhibitors and methods of using the same
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
CA2681162C (en) Benzyl and pyridine derivatives as modulators of hedgehog pathway
CN108794411B (zh) 某些化学实体、组合物及方法
CA2968633C (en) 2-aminopyrimidine compound and pharmaceutical composition and use thereof
US9024021B2 (en) Diarylacetylene hydrazide containing tyrosine kinase inhibitors
JP2023512038A (ja) 化合物及びその使用
US20110212053A1 (en) Phosphatidylinositol 3 kinase inhibitors
TW201906848A (zh) 化學化合物
Kankanala et al. Design, synthesis and biological evaluations of N-Hydroxy thienopyrimidine-2, 4-diones as inhibitors of HIV reverse transcriptase-associated RNase H
US20240327403A1 (en) PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES
WO2014079232A1 (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
CN108137534A (zh) 作为人免疫缺陷病毒复制的抑制剂的5-(n-苄基四氢异喹啉-6-基)吡啶-3-基乙酸衍生物
AU2004283093A1 (en) Compounds and compositions as protein kinase inhibitors
KR20070027723A (ko) 4,6-이치환된 피리미딘 및 단백질 키나제 억제제로서의이의 용도
CN106536482A (zh) 具有抗hiv作用的苯基和叔丁基乙酸取代的吡啶酮
CN114981256B (zh) 干扰素基因刺激物sting的单环激动剂
CN112851667B (zh) 含氮并杂环类化合物及其药用组合物和应用
Jin et al. Pyrrolo [2, 3-b] pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)